Market Research Logo

Personalized Medicine and Epigenomics: Technologies and Global Markets

Personalized Medicine and Epigenomics: Technologies and Global Markets

The global epigenomic market reached nearly $4 billion in 2014 and $4.7 billion in 2015. The market should reach nearly $12.1 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 20.6% from 2015 to 2020.

This report provides:
An overview of the global markets and technologies for personalized medicine and epigenomics.
Analyses global market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
Analysis of the current personalized medicine business model and the commercial use of the personalized medicine technology platform.
Evaluation of individual submarkets for personalized medicine in terms of technology, products, services, application areas and geography.
A look at the market's dynamics, specifically growth drivers, restraints, and opportunities.
Profiles of major players in the industry.


SCOPE OF THE REPORT

The report will analyze the market by types, products and applications. It will also focus on emerging technologies and therapies. Geographically, the market is divided into five regions: North America, Europe, the Asia-Pacific region and Latin America, and the Middle East and Asia (MEA).
Products are segmented by reagents, kits, instruments, enzymes and services.
Technologies are segmented by DNA methylation, histone methylation and acetylation, MicroRNA modification.
Applications are segmented areas by diagnosis, prognosis, therapy optimization in routine clinical treatment and drug discovery.
Therapy areas are segmented by cancer treatment, neurological disorders, CVD and others, which includes the research and development (R&D) stage.
Cancer treatment is further broken down into hematological cancers, solid tumors, gastric cancer, lung cancer and others.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVE
TITLE DESCRIPTION
SCOPE OF THE REPORT
INTENDED AUDIENCE
RESEARCH METHODOLOGY
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL EPIGENOMIC MARKET BY REGION, THROUGH 2020 ($MILLIONS)
SUMMARY FIGURE GLOBAL EPIGENOMIC MARKET BY REGION, 2014-2020 ($MILLIONS)
CHAPTER 3 MARKET OVERVIEW
INTRODUCTION
NEW PARADIGM OF EPIGENOMICS
EPIGENOMICS AS IT FITS WITHIN GENOMICS
TECHNICAL SCOPE OF THIS REPORT
EPIGENOMIC MARKET POTENTIAL
EPIGENOMIC PRODUCTS
RESEARCH TOOLS AND REAGENTS
DIAGNOSTICS
DRUGS
TABLE 1 U.S. FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC
THERAPIES
TABLE 2 SELECTED EPIGENETIC THERAPIES IN CLINICAL DEVELOPMENT
GROWTH DRIVING FORCES
GROWTH IN LIFE SCIENCE FUNDING
EPIGENOMIC MAP CREATION
AGING POPULATIONS IN DEVELOPED COUNTRIES
NEED FOR BETTER CANCER THERAPIES
GROWTH IN PERSONALIZED MEDICINE
IMPORTANCE OF EPIGENETIC TECHNOLOGY
LIFECYCLE STATUS OF EPIGENOMIC TECHNOLOGIES
HISTORICAL BACKGROUND
EPIGENOMIC INDUSTRY
CHAPTER 4 EPIGENETIC DRUGS ON THE MARKET AND IN THE PIPELINE
OVERVIEW
DRUG CLASSIFICATION
TABLE 3 EPIGENETIC DRUG CLASSIFICATION WITH THERAPEUTIC POTENTIAL
DNMT INHIBITORS
Nucleoside Analogue Inhibitors
Non-Nucleoside Analogue Inhibitors
Antisense Oligonucleotides
TABLE 4 CLASSIFICATION ACCORDING TO POTENTIAL THERAPEUTIC USES AND DEVELOPMENTAL PHASES, 2005-2015
DNA METHYLATION
DNA Methyltransferases
FIGURE 1 AZAC AND 5-AZADC MECHANISM OF ACTION
HISTONE DEACETYLASE INHIBITORS
Histone Deacetylase Inhibitors' Roles in Mental Health
Histone Deacetylase Inhibitors Roles in Other Health Conditions
Epigenetic Drug Combinations
FIGURE 2 EPIGENETIC CHANGES IN CANCER INVOLVING THE METHYLATION OF TUMOR-SUPPRESSION GENES AND THE DEMETHYLATION OF PROMETASTATIC
GENES
EMERGING THERAPIES
LARGE-SCALE REGIONAL EPIGENOMIC PROJECTS
ENCYCLOPEDIA OF DNA ELEMENTS
INTERNATIONAL HUMAN EPIGENOME CONSORTIUM
Blueprint
Epigenomic Platform Program (Canada)
DEEP (Germany)
CREST/IHEC, Team Japan (Asia)
National Institutes of Health Roadmap Epigenomic Project
OTHER REGIONAL PROJECTS
Asia-Pacific Projects
Canadian and Australian Projects
European Epigenomic Projects
CHAPTER 5 PERSONALIZED MEDICINE BASED ON THERAPEUTICS
OVERVIEW
MARKET DYNAMICS
FIGURE 3 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020
EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT
HEMATOLOGICAL CANCERS
TABLE 5 FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES, 2004-2015
SOLID TUMORS
GASTRIC CANCER
LUNG CANCER
COLORECTAL CANCERS
EPIGENETIC PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS
HUNTINGTON'S DISEASE
ALZHEIMER'S DISEASE
DEPRESSION
MENTAL RETARDATION
PARKINSON'S DISEASE
EPIGENETIC PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASES
EPIGENETIC PERSONALIZED MEDICINE FOR OTHERS
MYELODYSPLASTIC SYNDROMES
TABLE 6 CLINICAL PICTURE OF PERSONALIZED MEDICINE IN MYELODYSPLASTIC
SYNDROMES (2015)
OBESITY
DIABETES
RHEUMATOID ARTHRITIS
MULTIPLE SCLEROSIS
TABLE 7 EPIGENETIC MECHANISMS IMPLICATED IN MULTIPLE SCLEROSIS
PATHOGENESIS
INFLAMMATORY BOWEL DISEASES
CHAPTER 6 EPIGENETIC THERAPIES
STEM CELL THERAPIES
DIABETES
MENTAL DISORDERS
SEASONAL AFFECTIVE DISORDER
UNIPOLAR DEPRESSION
DYSTHYMIA OR DYSTHYMIA DISORDER
ATYPICAL DEPRESSION
PSYCHOTIC DEPRESSION
CHAPTER 7 BIOMARKER TECHNIQUES
BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION DNA
METHYLATION
CHROMATIN REMODELING
MIRNAS
miRNA Detection
MARKET DYNAMICS FOR EPIGENETIC DRUGS AND BIOMARKER DISCOVERY
DRIVERS
Increasing Prevalence of Cancer and Other Chronic Diseases
TABLE 8 GLOBAL CANCER INCIDENCES, 2012
Growing Global Geriatric Population Base
FIGURE 4 POPULATION AGE 65 AND OLDER, 2010-2030 (%)
Increasing Collaborations between Biotechnology and Pharmaceutical
Companies and Academic Research Institutes
TABLE 9 MAJOR COLLABORATIONS IN THE EPIGENETIC MARKET, 2011-2015
Presence of Funding Programs to Promote and Support Research and
Development
TABLE 10 KEY GLOBAL ORGANIZATIONS FUNDING EPIGENOMICS RELATED R&D, 2004-2015
Introduction of Technological Advancements
RESTRAINTS
Inefficiency to Identification and Validation of Biomarkers
Presence of Complicated Regulatory Framework
CHAPTER 8 EPIGENETIC NON-CANCER DIAGNOSIS
FIGURE 5 EPIGENOMIC ANALYSIS
NEURO
ALZHEIMER'S DISEASE
RESEARCH AND DEVELOPMENT
DEPRESSION
MENTAL RETARDATION
CARDIOVASCULAR DISEASE
TABLE 11 GLOBAL IMPACT OF CARDIOVASCULAR DISEASE, 2013 (MILLIONS)
FIGURE 6 POPULATION AFFECTED IN HIGH-, MIDDLE- AND LOW-INCOME COUNTRIES BY TYPE OF HEART DISEASE, 2012 (%)
FIGURE 7 GLOBAL CARDIOVASCULAR DISEASE PERCENTAGE, 2012 (%)
RESEARCH AND DEVELOPMENT IN EPIGENETICS CREATING HUGE SCOPE
FIGURE 8 EPIGENETIC ADVANCEMENT IN CARDIOVASCULAR DISEASES
HEART FAILURE
INFLAMMATORY AND AUTOIMMUNE DISEASE
RHEUMATOID ARTHRITIS
DIABETES
MULTIPLE SCLEROSIS
FIGURE 9 EPIGENETICS MECHANISM
INFLAMMATORY BOWEL DISEASES
LUPUS
RESEARCH AND DEVELOPMENT
DNA METHYLATION IN CANCER DETECTION
IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
MECHANISMS OF EPIGENETIC GENE SILENCING
CHAPTER 9 EPIGENETIC APPLICATIONS
EPIGENETICS DURING EARLY EMBRYONIC STAGES
PRE-IMPLANTATION REPROGRAMMING
Fusion and Cleavage
Demethylation and Remethylation in Early Embryos
Epigenetic Reprogramming in Later Development
Gene Expression and its Development in Clones and Technical
Contributions
GAMETOGENIC REPROGRAMMING
MITOCHONDRIAL HETEROPLASMY
IMPLICATIONS OF EPIGENETIC REPROGRAMMING ON ANIMAL HEALTH AND FOOD CONSUMPTION RISKS
REPROGRAMMING FACTORS
EPIGENETIC PROFILE OF MESENCHYMAL STEM CELLS IN CULTURE
TABLE 12 INDICATIONS AND OUTCOMES
CHAPTER 10 EPIGENOMICS: REGIONAL ANALYSIS
OVERVIEW
NORTH AMERICA
FIGURE 10 NORTH AMERICAN EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
TABLE 13 NORTH AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
TABLE 14 NORTH AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 15 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 16 NORTH AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 17 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
TABLE 18 NORTH AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT MARKET BY TYPE, THROUGH 2020 ($ MILLIONS)
TABLE 19 NORTH AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
TABLE 20 NORTH AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
TABLE 21 NORTH AMERICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
TABLE 22 NORTH AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS, THROUGH 2020 ($ MILLIONS)
TABLE 23 NORTH AMERICAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 24 NORTH AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 25 NORTH AMERICAN MARKET FOR HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, THROUGH 2020 ($ MILLIONS)
TABLE 26 NORTH AMERICAN EPIGENETIC DIAGNOSTIC MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 27 NORTH AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 28 NORTH AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 29 NORTH AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 30 NORTH AMERICAN EPIGENOMIC RESEARCH AND DEVELOPMENT MARKET, THROUGH 2020 ($ MILLIONS)
ASIA-PACIFIC
FIGURE 11 ASIA-PACIFIC EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
TABLE 31 ASIA-PACIFIC EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
TABLE 32 ASIA-PACIFIC EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 33 ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 34 ASIA-PACIFIC EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 35 ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 36 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT, THROUGH 2020 ($ MILLIONS)
TABLE 37 ASIA-PACIFIC EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
TABLE 38 ASIA-PACIFIC EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BY THERAPEUTIC, THROUGH 2020 ($ MILLIONS)
TABLE 39 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
TABLE 40 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 41 ASIA-PACIFIC EPIGENETIC THERAPY MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 42 ASIA-PACIFIC BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 43 ASIA-PACIFIC HISTONIC MODIFICATION AS A BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 44 ASIA-PACIFIC EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 45 ASIA-PACIFIC EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 46 ASIA-PACIFIC EPIGENETIC MARKET FOR CARDIOVASCULAR DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
TABLE 47 ASIA-PACIFIC EPIGENETIC MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
TABLE 48 ASIA-PACIFIC EPIGENETIC MARKET FOR RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
EUROPE
FIGURE 12 EUROPE EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
TABLE 49 EUROPEAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
TABLE 50 EUROPEAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH ($ MILLIONS)
TABLE 51 EUROPEAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 52 EUROPEAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 53 EUROPEAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
TABLE 54 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
TABLE 55 EUROPEAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($MILLIONS)
TABLE 56 EUROPEAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
TABLE 57 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
TABLE 58 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 59 EUROPEAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($MILLIONS)
TABLE 60 EUROPEAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 61 EUROPEAN HISTONIC MODIFICATION AS BIOMARKER MARKET IN CANCER DETECTION, THROUGH 2020 ($ MILLIONS)
TABLE 62 EUROPEAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 63 EUROPEAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 64 EUROPEAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 65 EUROPEAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 66 EUROPEAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
LATIN AMERICA
FIGURE 13 LATIN AMERICAN EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
TABLE 67 LATIN AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
TABLE 68 LATIN AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 69 LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 70 LATIN AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 71 LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 72 LATIN AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
TABLE 73 LATIN AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
TABLE 74 LATIN AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
TABLE 75 LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
TABLE 76 LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
TABLE 77 LATIN AMERICAN EPIGENETIC THERAPY MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 78 LATIN AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 79 LATIN AMERICAN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 80 LATIN AMERICAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 81 LATIN AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 82 LATIN AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET,THROUGH 2020 ($ MILLIONS)
TABLE 83 LATIN AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 84 LATIN AMERICAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
MIDDLE EAST AND AFRICA
FIGURE 14 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS)
TABLE 85 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($ MILLIONS)
TABLE 86 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 87 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
TABLE 88 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 ($ MILLIONS)
TABLE 89 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 ($ MILLIONS)
TABLE 90 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY TYPE, THROUGH 2020 ($ MILLIONS)
TABLE 91 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
TABLE 92 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS)
TABLE 93 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS)
TABLE 94 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED
MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS)
TABLE 95 MIDDLE EAST AND AFRICA EPIGENETIC THERAPY MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 96 MIDDLE EAST AND AFRICA BIOMARKER MARKET, THROUGH 2020 ($MILLIONS)
TABLE 97 MIDDLE EAST AND AFRICA HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 98 MIDDLE EAST AND AFRICA EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 99 MIDDLE EAST AND AFRICA EPIGENETIC NEURO DIAGNOSIS MARKET,THROUGH 2020 ($ MILLIONS)
TABLE 100 MIDDLE EAST AND AFRICA EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 101 MIDDLE EAST AND AFRICA EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS)
TABLE 102 MIDDLE EAST AND AFRICA EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 ($ MILLIONS)
CHAPTER 11 PRODUCT ANALYSIS
REAGENTS
FIGURE 15 GLOBAL EPIGENOMIC MARKET FOR REAGENTS, 2014-2020 ($ MILLIONS)
TABLE 103 GLOBAL EPIGENOMIC MARKET FOR REAGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
KITS
FIGURE 16 GLOBAL EPIGENOMIC MARKET FOR KITS, 2014-2020 ($ MILLIONS)
TABLE 104 GLOBAL EPIGENOMIC MARKET FOR KITS BY REGION, THROUGH 2020 ($ MILLIONS)
INSTRUMENTS
FIGURE 17 GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS, 2014-2020 ($MILLIONS)
TABLE 105 GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS BY REGION, THROUGH 2020 ($ MILLIONS)
ENZYMES
FIGURE 18 GLOBAL EPIGENOMIC MARKET FOR ENZYMES, 2014-2020 ($ MILLIONS)
TABLE 106 GLOBAL EPIGENOMIC MARKET FOR ENZYMES BY REGION, THROUGH 2020 ($ MILLIONS)
SERVICES
FIGURE 19 GLOBAL EPIGENOMIC MARKET FOR SERVICES, 2014-2020 ($ MILLIONS)
TABLE 107 GLOBAL EPIGENOMIC MARKET FOR SERVICES BY REGION, THROUGH 2020 ($ MILLIONS)
CHAPTER 12 ANALYSIS BY TECHNOLOGY
DNA METHYLATION
FIGURE 20 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION, 2014-2020 ($ MILLIONS)
TABLE 108 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION BY REGION, THROUGH 2020 ($ MILLIONS)
HISTONE METHYLATION AND ACETYLATION
FIGURE 21 GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION, 2014-2020 ($ MILLIONS)
TABLE 109 GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION BY REGION, THROUGH 2020 ($ MILLIONS)
MICRORNA MODIFICATION
FIGURE 22 GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION, THROUGH 2020 ($ MILLIONS)
TABLE 110 GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION BY REGION, THROUGH 2020 ($ MILLIONS)
CHAPTER 13 ANALYSIS BY APPLICATION
ONCOLOGY
FIGURE 23 GLOBAL EPIGENOMIC MARKET IN ONCOLOGY, 2014-2020 ($ MILLIONS)
TABLE 111 GLOBAL EPIGENOMIC MARKET IN ONCOLOGY BY REGION, THROUGH 2020 ($ MILLIONS)
NON-ONCOLOGY
FIGURE 24 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, 2014-2020 ($ MILLIONS)
TABLE 112 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, BY REGION, THROUGH 2020 ($ MILLIONS)
CANCER DRUG TECHNOLOGY
DNA METHYLTRANSFERASE INHIBITORS
FIGURE 25 GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS, 2014-2020 ($ MILLIONS)
TABLE 113 GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS BY REGION, THROUGH 2020 ($ MILLIONS)
HISTONE DEACETYLASE INHIBITORS
FIGURE 26 GLOBAL EPIGENOMIC MARKET IN HISTONE DEACETYLASE INHIBITORS, 2014-2020 ($ MILLIONS)
TABLE 114 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY BY REGION, THROUGH 2020 ($ MILLIONS)
APPLICATION AREAS
DIAGNOSIS
FIGURE 27 GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS, 2014-2020 ($ MILLIONS)
TABLE 115 GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS BY REGION, THROUGH 2020 ($ MILLIONS)
PROGNOSIS
FIGURE 28 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 ($ MILLIONS)
TABLE 116 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS BY REGION, THROUGH 2020 ($ MILLIONS)
THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT
FIGURE 29 GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT, 2014-2020 ($ MILLIONS)
TABLE 117 GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT BY REGION, THROUGH 2020 ($ MILLIONS)
DRUG DISCOVERY
FIGURE 30 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 ($ MILLIONS)
TABLE 118 GLOBAL EPIGENOMIC MARKET IN DRUG DISCOVERY BY REGION, THROUGH 2020 ($ MILLIONS)
CHAPTER 14 ANALYSIS BY PERSONALIZED MEDICINES
FIGURE 31 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020 ($ MILLIONS)
TABLE 119 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 32 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, 2014-2020 ($ MILLIONS)
TABLE 120 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE
FIGURE 33 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, 2014-2020 ($ MILLIONS)
TABLE 121 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
HEMATOLOGICAL CANCERS
FIGURE 34 GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS, 2014-2020 ($ MILLIONS)
TABLE 122 GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS BY REGION, THROUGH 2020 ($ MILLIONS)
Solid Tumors
FIGURE 35 GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS, 2014-2020 ($ MILLIONS)
TABLE 123 GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS BY REGION, THROUGH 2020 ($ MILLIONS)
GASTRIC CANCER
FIGURE 36 GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER, 2014-2020 ($ MILLIONS)
TABLE 124 GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
LUNG CANCER
FIGURE 37 GLOBAL EPIGENOMIC MARKET IN LUNG CANCER, 2014-2020 ($MILLIONS)
TABLE 125 GLOBAL EPIGENOMIC MARKET IN LUNG CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS
HUNTINGTON'S DISEASE
FIGURE 38 GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, 2014-2020 ($ MILLIONS)
TABLE 126 GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
ALZHEIMER'S DISEASE
FIGURE 39 GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE, 2014-2020 ($ MILLIONS)
TABLE 127 GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE BY REGION, THROUGH 2020 ($ MILLIONS)
DEPRESSION
FIGURE 40 GLOBAL EPIGENOMIC MARKET IN DEPRESSION, 2014-2020 ($ MILLIONS)
TABLE 128 GLOBAL EPIGENOMIC MARKET IN DEPRESSION BY REGION, THROUGH 2020 ($ MILLIONS)
MENTAL RETARDATION
FIGURE 41 GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION, 2014-2020 ($ MILLIONS)
TABLE 129 GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION BY REGION, THROUGH 2020 ($ MILLIONS)
PARKINSON'S DISEASE
FIGURE 42 GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, 2014-2020 ($ MILLIONS)
TABLE 130 GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS)
PERSONALIZED MEDICINE FOR OTHERS
MYELODYSPLASTIC SYNDROMES
FIGURE 43 GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES, 2014-2020 ($ MILLIONS)
TABLE 131 GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES BY REGION, THROUGH 2020 ($ MILLIONS)
OBESITY
FIGURE 44 GLOBAL EPIGENOMIC MARKET IN OBESITY, 2014-2020 ($ MILLIONS)
TABLE 132 GLOBAL EPIGENOMIC MARKET IN OBESITY, BY REGION, THROUGH 2020 ($ MILLIONS)
DIABETES
FIGURE 45 GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 ($ MILLIONS)
TABLE 133 GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 ($ MILLIONS)
RHEUMATOID ARTHRITIS
FIGURE 46 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 ($ MILLIONS)
TABLE 134 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
MULTIPLE SCLEROSIS
FIGURE 47 GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS, 2014-2020 ($ MILLIONS)
TABLE 135 GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS BY REGION, THROUGH 2020 ($ MILLIONS)
INFLAMMATORY BOWEL DISEASES
FIGURE 48 GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES, 2014-2020 ($ MILLIONS)
TABLE 136 GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
LUPUS
FIGURE 49 GLOBAL EPIGENOMIC MARKET IN LUPUS, 2014-2020 ($ MILLIONS)
TABLE 137 GLOBAL EPIGENOMIC MARKET IN LUPUS BY REGION, THROUGH 2020 ($ MILLIONS)
STEM CELL THERAPIES
FIGURE 50 GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES, 2014-2020 ($ MILLIONS)
TABLE 138 GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES BY REGION, THROUGH 2020 ($ MILLIONS)
TISSUE RE-ENGINEERING
FIGURE 51 GLOBAL EPIGENOMIC MARKET IN TISSUE RE-ENGINEERING, 2014-2020 ($ MILLIONS)
TABLE 139 GLOBAL EPIGENOMIC MARKET IN TISSUE REENGINEERING BY REGION, THROUGH 2020 ($ MILLIONS)
DIABETES
FIGURE 52 GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 ($ MILLIONS)
TABLE 140 GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 ($ MILLIONS)
RHEUMATOID ARTHRITIS
FIGURE 53 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 ($ MILLIONS)
TABLE 141 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 ($ MILLIONS)
MENTAL DISORDERS
FIGURE 54 GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS, 2014-2020 ($ MILLIONS)
TABLE 142 GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
CARDIAC DYSFUNCTION
FIGURE 55 GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION, 2014-2020 ($ MILLIONS)
TABLE 143 GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION BY REGION, THROUGH 2020 ($ MILLIONS)
CANCER
FIGURE 56 GLOBAL EPIGENOMIC MARKET IN CANCER, 2014-2020 ($ MILLIONS)
TABLE 144 GLOBAL EPIGENOMIC MARKET IN CANCER BY REGION, THROUGH 2020 ($ MILLIONS)
BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION
FIGURE 57 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION FOR CANCER DETECTION, 2014-2020 ($ MILLIONS)
TABLE 145 GLOBAL EPIGENOMIC MARKET IN BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION BY REGION, THROUGH 2020 ($ MILLIONS)
HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
FIGURE 58 GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, 2014-2020 ($ MILLIONS)
TABLE 146 GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 59 GLOBAL EPIGENOMICS MARKET IN CHROMATIN REMODELING, 2014-2020 ($ MILLIONS)
TABLE 147 GLOBAL EPIGENOMIC MARKET IN CHROMATIN REMODELING BY REGION, THROUGH 2020 ($ MILLIONS)
NONCODING RNAS
FIGURE 60 GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS, 2014-2020 ($ MILLIONS)
TABLE 148 GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 61 GLOBAL EPIGENOMIC MARKET IN MIRNAS, 2014-2020 ($ MILLION)
TABLE 149 GLOBAL EPIGENOMIC MARKET IN MIRNAS BY REGION, THROUGH 2020 ($ MILLIONS)
CHAPTER 15 COMPANY PROFILES
ABBOTT LABORATORIES
TABLE 150 ABBOTT PRODUCT PORTFOLIO
TABLE 151 ABBOTT RECENT DEVELOPMENTS
AFFYMETRIX
TABLE 152 AFFYMETRIX PRODUCT PORTFOLIO
TABLE 153 AFFYMETRIX RECENT DEVELOPMENTS
AGILENT TECHNOLOGIES
TABLE 154 AGILENT PRODUCT PORTFOLIO
TABLE 155 AGILENT'S RECENT DEVELOPMENTS
ASTELLAS PHARMACEUTICALS
TABLE 156 ASTELLAS PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE 157 ASTELLAS PHARMACEUTICALS RECENT DEVELOPMENTS
BAYER AG
TABLE 158 BAYER PRODUCT PORTFOLIO
TABLE 159 BAYER RECENT DEVELOPMENTS
BIO VISION
TABLE 160 BIO VISION PRODUCT PORTFOLIO
TABLE 161 BIO VISION RECENT DEVELOPMENTS
CELGENE CORP.
TABLE 162 CELGENE PRODUCT PORTFOLIO
EMD MILLIPORE
TABLE 163 EMD MILLIPORE PRODUCT PORTFOLIO
TABLE 164 EMD MILLIPORE RECENT DEVELOPMENTS
EPIGENOMICS AG
TABLE 165 EPIGENOMICS PRODUCT PORTFOLIO
TABLE 166 EPIGENOMICS RECENT DEVELOPMENTS
EPIGENTEX
TABLE 167 EPIGENTEK PRODUCT PORTFOLIO
TABLE 168 EPIGENTEK RECENT DEVELOPMENTS
ENVIVO PHARMACEUTICALS (FORUM PHARMACEUTRICALS)
GILEAD SCIENCES
TABLE 169 GILEAD SCIENCES PRODUCT PORTFOLIO
TABLE 170 GILEAD SCIENCES RECENT DEVELOPMENTS
GLAXOSMITHKLINE
TABLE 171 GLAXOSMITHKLINE PRODUCT PORTFOLIO
ILLUMINA INC.
TABLE 172 ILLUMINA PRODUCT PORTFOLIO
TABLE 173 ILLUMINA RECENT DEVELOPMENTS
JOHNSON & JOHNSON
TABLE 174 JOHNSON & JOHNSON PRODUCT PORTFOLIO
KARUS THERAPEUTICS LIMITED
TABLE 175 KARUS THERAPEUTICS PRODUCT PORTFOLIO
LABORATORY CORP. OF AMERICA HOLDINGS
TABLE 176 LABCORP PRODUCT PORTFOLIO
TABLE 177 LABCORP RECENT DEVELOPMENTS
LES LABORATOIRES SERVIER
TABLE 178 LES LABORATOIRES SERVIER RECENT DEVELOPMENTS
MERCK SHARP & DOHME
NATUREWISE BIOTECH & MEDICALS CORP.
NOVARTIS PHARMA AG
TABLE 179 NOVARTIS PRODUCT PORTFOLIO
TABLE 180 NOVARTIS RECENT DEVELOPMENTS
ONCOLYS BIOPHARMA INC.
TABLE 181 ONCOLYS BIOPHARMA PRODUCT PORTFOLIO
TABLE 182 ONCOLYS BIOPHARMA RECENT DEVELOPMENTS
ORCHID CHEMICALS & PHARMACEUTICALS LIMITED
TABLE 183 ORCHID CHEMICALS & PHARMACEUTICALS PRODUCT PORTFOLIO
PROGEN PHARMACEUTICALS LIMITED
TABLE 184 PROGEN PHARMA PRODUCT PORTFOLIO
QUEST DIAGNOSTICS
TABLE 185 QUEST DIAGNOSTICS PRODUCT PORTFOLIO
TABLE 186 QUEST DIAGNOSTICS RECENT DEVELOPMENTS
ROCHE HOLDING AG
TABLE 187 ROCHE'S PRODUCT PORTFOLIO
TABLE 188 ROCHE'S RECENT DEVELOPMENTS
RUBICON GENOMICS
TABLE 189 RUBICON GENOMICS PRODUCT PORTFOLIO
TABLE 190 RUBICON GENOMICS RECENT DEVELOPMENTS
TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 191 TAKEDA PHARMACEUTICALS PRODUCT PORTFOLIO
CHAPTER 16 PATENT ANALYSIS
LIST OF PATENTS
U.S.
TABLE 192 U.S. PATENTS, 2011-JULY 2015
EUROPEAN AND JAPANESE PATENTS
TABLE 193 EUROPEAN AND JAPANESE PATENTS, 2011-JULY 2015
JAPANESE PATENTS
TABLE 194 JAPANESE PATENTS, 2011--NOVEMBER 2014

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report